Compare Abbott Laboratories (ABT) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Caesars Entertainment Inc — how do they compare? Abbott Laboratories trades at $95.43 (market cap $166.94B), while Caesars Entertainment Inc trades at $29.87 (market cap $6.18B). The key difference: Abbott Laboratories is far larger — about 27× Caesars Entertainment Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Caesars Entertainment Inc pays none. Which is the better fit depends on your goals.
| ABT | CZR | |
|---|---|---|
Market Cap | $166.94B | $6.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $31.51 |
52-Week Low | $82.57 | $18.14 |
Enterprise Value | $193.69B | $30.24B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CZR trades at $30.35, down 0.13% with a neutral technical stance despite bullish moving averages. The company reported a net loss of $502M in 2025 with negative margins, though revenue grew to $11.49B. Valuation ratios like P/E of 10.42 and P/S of 0.54 appear attractive, but recent earnings misses and a pending acquisition by Fertitta Entertainment at $31.00 per share dominate sentiment. Cash flow trends show improving operational performance with net cash flow narrowing to -$32M in 2025.
The outlook is mixed: the acquisition offers a near-term floor, but operational losses and high debt of $12.03B pose risks. Analysts are cautious with 63.3% hold ratings, citing competitive pressures and integration uncertainties. Investors should weigh the buyout premium against fundamental weaknesses in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
